Victory Capital Management Inc. acquired a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,658 shares of the company’s stock, valued at approximately $104,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in CODX. Credit Agricole S A acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $48,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $99,000. Goldman Sachs Group Inc. acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $109,000. Cannon Global Investment Management LLC acquired a new stake in Co-Diagnostics during the 2nd quarter valued at approximately $135,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Co-Diagnostics by 35.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 21,390 shares of the company’s stock valued at $204,000 after acquiring an additional 5,645 shares during the period. Institutional investors and hedge funds own 25.25% of the company’s stock.
Several research firms recently issued reports on CODX. Zacks Investment Research cut shares of Co-Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Co-Diagnostics in a research note on Friday.
Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings results on Thursday, August 12th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.22 by $0.11. The company had revenue of $27.36 million during the quarter, compared to analyst estimates of $21.00 million. Co-Diagnostics had a net margin of 47.98% and a return on equity of 65.33%. Analysts forecast that Co-Diagnostics, Inc. will post 0.95 earnings per share for the current fiscal year.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Want to see what other hedge funds are holding CODX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Co-Diagnostics, Inc. (NASDAQ:CODX).
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.